E are several humanized variants. Some of these variants has in vitro activity of t Lost the battle against the spread, despite a strong affinity t t for HER2, but other deductions against the spread and the effectiveness of this clone was placed for further Hlt Hlt Rolipram ZK 62711 clinical development. The constant regions of monoclonal humanized organs are green He optimal participation Corps surveilance old t-dependent-Dependent cellular Re cytotoxicity t or complement-dependent-Dependent cytotoxicity t Re Con C and even trastuzumab is more effective than the murine homolog of mediated ADCC. Trastuzumab reduced from cell culture 4D5 mouse anti-proliferative, but also strong anti-tumor activity of T In mouse xenograft models.
Clinical anti-tumor activity of t Tt of clinical tumor control trastuzumab trastuzumab was largely by numerous clinical studies in the last decade and a half difficulties H. Nglichen ANF to HER2 overexpressing the subset of patients with tumors clinically available by immunohistochemical methods after all by clinical examination of the fluorescence in situ hybridization beaten identify HER2 Roscovitine gene amplification and discover it is now clear that trastuzumab induces tumor regression in 30-35% of patients with metastatic HER2 verst RKT when initial therapy and activity dd used to be, at least, when used with other chemotherapies. Patients with metastatic disease, trastuzumab is not curative and the disease takes a median of 5 months, despite continued treatment with trastuzumab. With most clinical benefit from trastuzumab was different cytotoxic chemotherapy.
The addition of trastuzumab to chemotherapy increased Fa hte Ht is its multiple significant anti-tumor efficacy. Th gr effects of trastuzumab was early in the treatment of patients with potentially curable breast cancer. HER2 verst RKT patients with breast cancer again Oivent chemotherapy after surgical resection of the experimental groups, the addition of trastuzumab to chemotherapy significantly their Ngeren survive disease-free and the risk of recurrence. Although these studies of adjuvant therapy is still in its early years of monitoring is the strong effect of the early follow-up period, the well-t as a significant reduction in mortality Considered in breast cancer HER2-amplified t with trastuzumab quickly lead to default treatment for patients with early breast cancer.
The antitumor activity of t Trastuzumab t tumors overexpress HER2, trastuzumab and had limited no clinically significant effect against breast cancer without HER2 overexpression. At that time his activity T seems not evaluated monotherapy Descr breast cancer and also a lot less t Antitumoraktivit clinic against cancer Rmutterschleimhaut building Building and ovarian cancer with HER2 overexpression and continue to investigate other types of cancer. These improvements in the clinical management of patients with HER2 trastuzumab RKT verst offerings are a direct result of the HER2 oncogene hypothesis of breast cancer originally proposed two decades ago, and are a testament to the potential impact of scientific research on human health and